Last reviewed · How we verify
A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies
PRIMARY OBJECTIVES: I. To document the toxicities, and reversibility of toxicities, of this regimen of 5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride). SECONDARY OBJECTIVES: I. To determine any potential anti-tumor effects, as determined by the objective tumor response (complete and partial responses), clinical benefit (complete and partial responses, and clinical benefit), the time to tumor response, the time to tumor progression, and the overall survival.
Details
| Lead sponsor | New Mexico Cancer Research Alliance |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | 2008-06 |
| Completion | 2011-09 |
Conditions
- Advanced Solid Tumor Malignancies
Interventions
- 5-azacytidine, erlotinib
- Erlotinib PO and Vidaza IV
Primary outcomes
- Quality and quantity of adverse events due to administration of erlotinib + 5-azacytidine, as therapy for the treatment of advanced or metastatic cancer. — 4 years
Countries
United States